Cargando…

Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype

DESIGN: Rapid CD4 cell loss represents an HIV phenotype used to identify causal variants of accelerated disease progression. The optimal rate and threshold for identifying this extreme phenotype in recently infected individuals is unclear. METHODS: Using a cohort of patients with known dates of HIV-...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, Ashley D., Guiguet, Marguerite, Zangerle, Robert, Gill, John, Perez-Hoyos, Santiago, Lodi, Sara, Ghosn, Jade, Dorrucci, Maria, Johnson, Anne, Sannes, Mette, Moreno, Santiago, Porter, Kholoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134321/
https://www.ncbi.nlm.nih.gov/pubmed/24872130
http://dx.doi.org/10.1097/QAI.0000000000000240
_version_ 1782330866024841216
author Olson, Ashley D.
Guiguet, Marguerite
Zangerle, Robert
Gill, John
Perez-Hoyos, Santiago
Lodi, Sara
Ghosn, Jade
Dorrucci, Maria
Johnson, Anne
Sannes, Mette
Moreno, Santiago
Porter, Kholoud
author_facet Olson, Ashley D.
Guiguet, Marguerite
Zangerle, Robert
Gill, John
Perez-Hoyos, Santiago
Lodi, Sara
Ghosn, Jade
Dorrucci, Maria
Johnson, Anne
Sannes, Mette
Moreno, Santiago
Porter, Kholoud
author_sort Olson, Ashley D.
collection PubMed
description DESIGN: Rapid CD4 cell loss represents an HIV phenotype used to identify causal variants of accelerated disease progression. The optimal rate and threshold for identifying this extreme phenotype in recently infected individuals is unclear. METHODS: Using a cohort of patients with known dates of HIV-1 seroconversion (SC), CASCADE (Concerted Action on SeroConversion on AIDS and Death in Europe), we identified proportions experiencing nadir CD4 cell levels within 1 year of SC, and assessed their mean AIDS-free survival time at 10-year follow-up and hazard of AIDS/death, compared with those whose CD4 remained >500 cells per cubic millimeter. Follow-up was censored at December 31, 1996 to avoid bias due to combination antiretroviral therapy initiation. RESULTS: Of 4876 individuals, 2.8%, 7.3%, and 24.9% experienced ≥1 CD4 <100, 200, and 350 cells per cubic millimeter, respectively, within 1 year of SC. Minimum CD4 levels of 30, 166, 231, and 506 cells per cubic millimeter were experienced during this period by 1%, 5%, 10%, and 50% of individuals, respectively. Mean (95% confidence interval) AIDS-free survival at 10 years follow-up was 2.9 (2.3 to 3.6), 5.5 (5.0 to 6.1), 6.7 (6.5 to 7.0), 7.4 (7.2 to 7.6), and 8.1 (7.9 to 8.3), for those with minimum counts ≤100, 100–200, 200–350, 350–500, >500 cells per cubic millimeter, respectively. Using counts of >500 cells per cubic millimeter as reference, the hazard ratios (95% confidence interval) of AIDS/death were 15.0 (11.9 to 18.9), 3.6 (2.9 to 4.5), 2.1 (1.8 to 2.4), and 1.5 (1.3 to 1.7), respectively. The hazard ratio increased to 37.5 (26.5 to 53.1) when a minimum CD4 count <100 was confirmed within 1 year of SC. CONCLUSION: At least 1 CD4 ≤100 cells per cubic millimeter within the first year of SC identifies a rare group of individuals at high risk of disease progression and could form the basis for defining the rapid progressor phenotype.
format Online
Article
Text
id pubmed-4134321
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher JAIDS Journal of Acquired Immune Deficiency Syndromes
record_format MEDLINE/PubMed
spelling pubmed-41343212014-09-01 Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype Olson, Ashley D. Guiguet, Marguerite Zangerle, Robert Gill, John Perez-Hoyos, Santiago Lodi, Sara Ghosn, Jade Dorrucci, Maria Johnson, Anne Sannes, Mette Moreno, Santiago Porter, Kholoud J Acquir Immune Defic Syndr Basic and Translational Science DESIGN: Rapid CD4 cell loss represents an HIV phenotype used to identify causal variants of accelerated disease progression. The optimal rate and threshold for identifying this extreme phenotype in recently infected individuals is unclear. METHODS: Using a cohort of patients with known dates of HIV-1 seroconversion (SC), CASCADE (Concerted Action on SeroConversion on AIDS and Death in Europe), we identified proportions experiencing nadir CD4 cell levels within 1 year of SC, and assessed their mean AIDS-free survival time at 10-year follow-up and hazard of AIDS/death, compared with those whose CD4 remained >500 cells per cubic millimeter. Follow-up was censored at December 31, 1996 to avoid bias due to combination antiretroviral therapy initiation. RESULTS: Of 4876 individuals, 2.8%, 7.3%, and 24.9% experienced ≥1 CD4 <100, 200, and 350 cells per cubic millimeter, respectively, within 1 year of SC. Minimum CD4 levels of 30, 166, 231, and 506 cells per cubic millimeter were experienced during this period by 1%, 5%, 10%, and 50% of individuals, respectively. Mean (95% confidence interval) AIDS-free survival at 10 years follow-up was 2.9 (2.3 to 3.6), 5.5 (5.0 to 6.1), 6.7 (6.5 to 7.0), 7.4 (7.2 to 7.6), and 8.1 (7.9 to 8.3), for those with minimum counts ≤100, 100–200, 200–350, 350–500, >500 cells per cubic millimeter, respectively. Using counts of >500 cells per cubic millimeter as reference, the hazard ratios (95% confidence interval) of AIDS/death were 15.0 (11.9 to 18.9), 3.6 (2.9 to 4.5), 2.1 (1.8 to 2.4), and 1.5 (1.3 to 1.7), respectively. The hazard ratio increased to 37.5 (26.5 to 53.1) when a minimum CD4 count <100 was confirmed within 1 year of SC. CONCLUSION: At least 1 CD4 ≤100 cells per cubic millimeter within the first year of SC identifies a rare group of individuals at high risk of disease progression and could form the basis for defining the rapid progressor phenotype. JAIDS Journal of Acquired Immune Deficiency Syndromes 2014-09-01 2014-08-13 /pmc/articles/PMC4134321/ /pubmed/24872130 http://dx.doi.org/10.1097/QAI.0000000000000240 Text en Copyright © 2014 by Lippincott Williams & Wilkins This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Basic and Translational Science
Olson, Ashley D.
Guiguet, Marguerite
Zangerle, Robert
Gill, John
Perez-Hoyos, Santiago
Lodi, Sara
Ghosn, Jade
Dorrucci, Maria
Johnson, Anne
Sannes, Mette
Moreno, Santiago
Porter, Kholoud
Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
title Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
title_full Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
title_fullStr Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
title_full_unstemmed Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
title_short Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype
title_sort evaluation of rapid progressors in hiv infection as an extreme phenotype
topic Basic and Translational Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134321/
https://www.ncbi.nlm.nih.gov/pubmed/24872130
http://dx.doi.org/10.1097/QAI.0000000000000240
work_keys_str_mv AT olsonashleyd evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT guiguetmarguerite evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT zangerlerobert evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT gilljohn evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT perezhoyossantiago evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT lodisara evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT ghosnjade evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT dorruccimaria evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT johnsonanne evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT sannesmette evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT morenosantiago evaluationofrapidprogressorsinhivinfectionasanextremephenotype
AT porterkholoud evaluationofrapidprogressorsinhivinfectionasanextremephenotype